Griffin Collins

Dr. Griffin Collins

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
SLSarah A. Lau-Braunhut
Sarah A. Lau-Braunhut
HSHannah Stone
Hannah Stone
GCGriffin Collins
Griffin Collins
SBSIGBJORN BERENTSEN
SIGBJORN BERENTSEN
BBBenjamin S. Braun
Benjamin S. Braun
MZMatt S. Zinter
Matt S. Zinter
Key Points: This is the first-ever demonstration of successful treatment of paroxysmal cold hemoglobinuria using the complement inhibitor eculizumab.

10 June 2023 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
DLDeena Levine
Deena Levine
RERebecca Epperly
Rebecca Epperly
GCGriffin Collins
Griffin Collins
ATAimee C. Talleur
Aimee C. Talleur
BMBelinda Mandrell
Belinda Mandrell
JBJustin N. Baker
Justin N. Baker

27 October 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
GCGriffin Collins
Griffin Collins
HBHannah Beaman
Hannah Beaman
AHAlvin M. Ho
Alvin M. Ho
MHMichelle Hermiston
Michelle Hermiston
HCHarvey J. Cohen
Harvey J. Cohen
EDElizabeth W. Dzeng
Elizabeth W. Dzeng

1 February 2023 in Journal of Pediatric Hematology/Oncology Nursing
Verified
Journal Article
Closed access
MRMaggie C. Root
Maggie C. Root
JKJane Koo
Jane Koo
GCGriffin Collins
Griffin Collins
NPNeela L. Penumarthy
Neela L. Penumarthy
MHMichelle Hermiston
Michelle Hermiston
JBJori F. Bogetz
Jori F. Bogetz
Background: Children with relapsed/refractory cancer have a myriad of palliative care needs. While pediatric oncology clinicians meet many of these needs, studies suggest that these children often have distressing symptoms and that families feel unprepared for their child's end-of-life (EOL). Oncology clinicians cite barriers to pediatric palliative care (PPC) consultation, including concerns that PPC teams will upset families with EOL discussions. This study evaluated topics addressed by PPC teams over the course of their relationship with children who died from cancer. Methods: Retrospective chart review of children who were diagnosed with relapsed/refractory cancer, received PPC consultation at an academic children's hospital, and died between January 2008 and January 2017. Information was extracted regarding the child's treatment, EOL care, and the content of PPC consultation over the course of the team's relationship with the child/family. Results: Fifty-six children were included in the analysis. The most frequent reasons for the initial consult were pain ( n = 31, 55%) and non-pain symptom management ( n = 18, 32%). At the initial consult, the PPC team most often discussed symptom management and psychosocial support. Prognosis was not discussed in any initial consult. Over subsequent visits, the PPC team expanded their scope of discussion to include goals of care, advance care planning, and hospice. Discussion: Concerns from oncology clinicians that PPC teams will extend beyond the reasons for initial consult into prognostic/EOL discussions at the first visit may be unfounded. Greater familiarity with PPC team practices may facilitate more timely consultation of PPC and its complementary set of services.

13 February 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GCGriffin Collins
Griffin Collins
DLDeena R. Levine
Deena R. Levine
ALAlexis Leonard
Alexis Leonard
ASAkshay Sharma
Akshay Sharma
LJLiza-Marie Johnson
Liza-Marie Johnson
People with severe sickle cell disease (SCD) are now presented with increasing access to curative-intent therapies including allogeneic hematopoietic stem cell transplantation (HCT) and gene therapy (GT). These high-risk, high-reward therapies offer hope for cure and prevention of further injury due to SCD, but they are toxic therapies that carry risk of additional morbidity and mortality. People with severe SCD suffer due to extreme pain and serious multi-system injury which is compounded by the effects of systemic racism. The increasing availability of these complex, sometimes novel, therapies with curative-intent highlights the role for specialist palliative care (PC) in the care of people with severe SCD. Multidisciplinary PC teams employ a holistic, person-centered approach to alleviating suffering by accompanying patients through high-stakes decision making, coping with life-threatening illness, and symptom management. The role for PC beginning early in HCT has been established, though PC is infrequently integrated in HCT. Little research exists regarding the role for PC in care of people with SCD. We present concepts of PC integration for people with SCD undergoing HCT or GT and advocate for PC integration beginning once patients consider a curative-intent therapy throughout the duration and following completion of treatment. As curative-intent therapies for patients with SCD continue to evolve, there is an opportunity for PC, HCT, and SCD teams to collaborate with patients to develop implementable models for high-quality, multidisciplinary care for people with severe SCD and their families.

1 April 2018 in Pediatrics
Verified
Journal Article
Closed access
PDF file
BSBryan A. Sisk
Bryan A. Sisk
GCGriffin Collins
Griffin Collins
CDClaire Dillenbeck
Claire Dillenbeck
JMJ. Jeffrey Malatack
J. Jeffrey Malatack
BACKGROUND: We determined types of peer-reviewed articles that cited Pediatrics case reports and whether citations were “appropriate” or “inappropriate.” METHODS: The 20 most highly cited Pediatrics case reports published between January 2011 and April 2016 were identified. All articles referencing these 20 case reports were analyzed for appropriateness of the citation. Appropriate citations referred to the original article specifically as a case report or cited the case report in support of general knowledge. Inappropriate citations used case reports to infer causation, support proof of mechanism, or were deemed irrelevant to claims being supported. Two authors independently coded all citations. RESULTS: These 20 case reports were cited in 479 articles (median: 24 citations per case report). In most articles (83.6%, n = 367), case reports were cited appropriately; in 53.4% (n = 196) of articles, a case report was specifically referred to, and in 46.6% (n = 171) of articles, the case report was used to support general knowledge. For inappropriate citations, in 63.3% (n = 50) of articles, case reports were used to infer causation; in 15.2% (n = 12) of articles, they were used as proof of mechanism of pathogenesis or treatment; and in 21.5% (n = 17) of articles, they were irrelevant. Case reports were most commonly cited in review articles (38.7%, n = 170) and original studies (31%, n = 136). “Original studies” were articles in which authors reported original data, excluding case reports. CONCLUSIONS: These results reveal that most citations of Pediatrics case reports are appropriate.